Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer.

Westin GF, Perez CA, Wang E, Glück S.

Int J Biol Markers. 2013 Sep 27;28(3):233-41. doi: 10.5301/JBM.5000040.

PMID:
23999849
2.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
3.

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E.

J Clin Oncol. 2012 Aug 1;30(22):2718-24. doi: 10.1200/JCO.2011.39.0708. Epub 2012 May 7.

4.

Challenges in the endocrine management of breast cancer.

Mouridsen HT, Rose C, Brodie AH, Smith IE.

Breast. 2003 Aug;12 Suppl 2:S2-19. Review.

PMID:
14659138
5.
6.

Everolimus: a new hope for patients with breast cancer.

Sendur MA, Zengin N, Aksoy S, Altundag K.

Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14. Review.

PMID:
24050600
7.

Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.

Gnant M, Greil R, Hubalek M, Steger G.

Breast Care (Basel). 2013 Aug;8(4):293-9. doi: 10.1159/000354121. Review.

8.

The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer.

Gnant M.

Curr Oncol Rep. 2013 Feb;15(1):14-23. doi: 10.1007/s11912-012-0277-1. Review.

PMID:
23054937
9.
10.

Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.

Nagaraj G, Ma C.

Breast Cancer Res Treat. 2015 Apr;150(2):231-42. doi: 10.1007/s10549-015-3316-4. Epub 2015 Mar 12. Review.

PMID:
25762475
11.

Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.

Jerusalem G, Rorive A, Collignon J.

Breast Cancer (Dove Med Press). 2014 Apr 17;6:43-57. doi: 10.2147/BCTT.S38679. eCollection 2014. Review.

12.

The role of aromatase inhibitors in early breast cancer.

Chung CT, Carlson RW.

Curr Treat Options Oncol. 2003 Apr;4(2):133-40. Review.

PMID:
12594939
13.

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.

Paplomata E, O'Regan R.

Ther Clin Risk Manag. 2013;9:27-36. doi: 10.2147/TCRM.S30349. Epub 2013 Jan 14.

14.
15.

Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer.

Parker LM.

Clin Ther. 2002;24 Suppl C:C43-57. Review.

PMID:
12117075
16.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Howell SJ, Johnston SR, Howell A.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.

PMID:
14687597
17.

Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.

Gligorov J, Lotz JP.

Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:53-66. doi: 10.1007/s10549-008-0232-x. Epub 2008 Dec 20.

PMID:
19101794
18.
19.
20.

Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.

Michaud LB, Buzdar AU.

Drugs Aging. 2000 Apr;16(4):261-71. Review.

PMID:
10874521
Items per page

Supplemental Content

Write to the Help Desk